Company Description

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.

Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022.

The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Lisata Therapeutics, Inc.

Country	United States
Founded	1980
Industry	Biotechnology
Sector	Healthcare
Employees	21
CEO	David Mazzo

Contact Details

Address: 110 Allen Road, 2nd Floor Basking Ridge, New Jersey 07920 United States
Phone	908 842 0100
Website	lisata.com

Stock Details

Ticker Symbol	LSTA
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0000320017
CUSIP Number	128058302
ISIN Number	US1280583022
Employer ID	22-2343568
SIC Code	2834

Key Executives

Name	Position
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.	Chief Executive Officer and Director
James Nisco	SVice President of Finance and Treasury and Chief Accounting Officer
Dr. Joshua Lehrer-Graiwer FACC, M.D.	President and Chief Operating Officer

Latest SEC Filings

Date	Type	Title
Oct 19, 2026	ARS	Filing
Oct 19, 2026	DEF 14A	Other definitive proxy statements
Oct 14, 2026	8-K	Current Report
Oct 7, 2026	PRE 14A	Other preliminary proxy statements
Oct 2, 2026	D	Notice of Exempt Offering of Securities
Sep 17, 2026	8-K	Current Report
Aug 26, 2026	SCHEDULE 13G	Filing
Aug 6, 2026	10-Q	Quarterly Report
Aug 4, 2026	8-K	Current Report
Jul 28, 2026	SC TO-T/A	Filing

View All SEC Filings